- Home
- PED vs CNTB Comparison
PED vs CNTB Comparison
Compare PED & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | CNTB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8M | 140.4M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PED | CNTB |
|---|---|---|
| Price | $13.34 | $1.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $30.00 | $8.67 |
| AVG Volume (30 Days) | 27.7K | ★ 1.6M |
| Earning Date | 05-15-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,751,000.00 | $64,000.00 |
| Revenue This Year | $171.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $0.43 | $1.06 |
| 52 Week High | $18.89 | $3.82 |
Technical Indicators
Market Signals| Indicator | PED | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 32.54 |
| Support Level | $14.12 | N/A |
| Resistance Level | $16.70 | $2.78 |
| Average True Range (ATR) | 1.08 | 0.26 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 27.86 | 11.45 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.